Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22597885 | 0.86 | USP2 (0.33) | — | |
| SCHEMBL25049540 | 0.86 | USP2 (0.33) | — | |
| SCHEMBL9607916 | 0.84 | NEK2 (0.30) | — | |
| SCHEMBL22488557 | 0.83 | DRD4 (0.32) | DRD4OPRM1 | |
| SCHEMBL22318070 | 0.83 | DRD4 (0.32) | DRD4OPRM1 | |
| SCHEMBL25684339 | 0.81 | DRD4 (0.31) | DRD4OPRM1 | |
| SCHEMBL23055301 | 0.80 | DRD4 (0.33) | DRD4OPRM1 | |
| SCHEMBL18911537 | 0.78 | — | — | |
| SCHEMBL17972978 | 0.73 | DRD4 (0.32) | DRD4OPRM1 | |
| SCHEMBL18968108 | 0.73 | SOS1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2861605-B1 | 6-Benzyl-6H-thieno[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5-one derivatives as phosphodiesterase-1 (PDE-1) inhibitors for the treatment of e.g. neurological, cognitive and cardiovascular disorders | DART NEUROSCIENCE (CAYMAN) LTD (KY) | 2017-05-03 | — | — | EP | claimed |
| US-9499562-B2 | Substituted thiophene- and furan-fused azolopyrimidine-5-(6H)-one compounds | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2016-11-22 | — | — | US | claimed |
| US-20160031901-A1 | SUBSTITUTED THIOPHENE- AND FURAN-FUSED AZOLOPYRIMIDINE-5-(6H)-ONE COMPOUNDS | DART NEUROSCIENCE LLC | 2016-02-04 | — | — | US | claimed |
| EP-3873903-B1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS AS HPK1 INHIBITORS | GILEAD SCIENCES INC (US) | 2024-01-24 | — | — | EP | disclosed |
| EP-3647311-B1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO LTD (CN) | 2023-11-01 | — | — | EP | disclosed |
| US-20230203007-A1 | PYRIDINYLACETAMIDE DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | X-CHEM GLOBAL HQ | 2023-06-29 | — | — | US | disclosed |
| US-20230203007-A1 | PYRIDINYLACETAMIDE DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | X-CHEM GLOBAL HQ | 2023-06-29 | — | — | US | disclosed |
| US-20230112485-A1 | THERAPEUTIC COMPOUNDS | GENENTECH, INC. (US) | 2023-04-13 | — | — | US | disclosed |
| EP-3932404-A1 | METHOD FOR TREATING FATTY LIVER DISEASE AND/OR STEATOHEPATITIS | Beijing Tide Pharmaceutical Co., Ltd. (CN) | 2022-01-05 | — | — | EP | disclosed |
| US-20210387963-A1 | PHENYLTETRAZOLE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-12-16 | — | — | US | disclosed |
| US-10695334-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-06-30 | — | — | US | disclosed |
| EP-3647311-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | Beijing Tide Pharmaceutical Co., Ltd. (CN) | 2020-05-06 | — | — | EP | disclosed |
| US-20200054617-A1 | Heteroaromatic Carboxamide Derivatives as Plasma Kallikrein Inhibitors | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2020-02-20 | — | — | US | disclosed |
| WO-2019001572-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | 北京泰德制药股份有限公司 | 2019-01-03 | — | — | WO | disclosed |
| US-10092575-B2 | Substituted thiophene- and furan-fused azolopyrimidine-5-(6H)-one compounds | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2018-10-09 | — | — | US | disclosed |
| US-20170209459-A1 | SUBSTITUTED THIOPHENE- AND FURAN-FUSED AZOLOPYRIMIDINE-5-(6H)-ONE COMPOUNDS | DART NEUROSCIENCE LLC | 2017-07-27 | — | — | US | disclosed |
| EP-2861605-B1 | 6-Benzyl-6H-thieno[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5-one derivatives as phosphodiesterase-1 (PDE-1) inhibitors for the treatment of e.g. neurological, cognitive and cardiovascular disorders | DART NEUROSCIENCE (CAYMAN) LTD (KY) | 2017-05-03 | — | — | EP | disclosed |
| US-9499562-B2 | Substituted thiophene- and furan-fused azolopyrimidine-5-(6H)-one compounds | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2016-11-22 | — | — | US | disclosed |
| US-20160031901-A1 | SUBSTITUTED THIOPHENE- AND FURAN-FUSED AZOLOPYRIMIDINE-5-(6H)-ONE COMPOUNDS | DART NEUROSCIENCE LLC | 2016-02-04 | — | — | US | disclosed |
| WO-2015091584-A1 | THIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND THEIR USE AS TYK2 KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10092575-B2 | Substituted thiophene- and furan-fused azolopyrimidine-5-(6H)-one compounds | TPMT, PSEN2, GRIN2C | DRD4 714/4885OPRM1 3546/4885 |
| US-20230112485-A1 | THERAPEUTIC COMPOUNDS | BRDT, BRPF3, SNRPE | DRD4 4779/4885OPRM1 4079/4885 |
| US-20160031901-A1 | SUBSTITUTED THIOPHENE- AND FURAN-FUSED AZOLOPYRIMIDINE-5-(6H)-ONE COMPOUNDS | TPMT, PSEN2, GRIN2C | DRD4 738/4885OPRM1 3381/4885 |
| US-20210387963-A1 | PHENYLTETRAZOLE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | KLKB1, SERPINE1, SERPINB1 | DRD4 4060/4885OPRM1 3925/4885 |
| US-20200054617-A1 | Heteroaromatic Carboxamide Derivatives as Plasma Kallikrein Inhibitors | KLKB1, KLK1, KLK5 | DRD4 4699/4885OPRM1 2233/4885 |
| US-20230203007-A1 | PYRIDINYLACETAMIDE DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | SCN1A, SCN3A, SCN2A | DRD4 3487/4885OPRM1 932/4885 |
| US-20170209459-A1 | SUBSTITUTED THIOPHENE- AND FURAN-FUSED AZOLOPYRIMIDINE-5-(6H)-ONE COMPOUNDS | TPMT, PSEN2, GRIN2C | DRD4 714/4885OPRM1 3546/4885 |
| US-10695334-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | KLKB1, KLK1, KLK5 | DRD4 4699/4885OPRM1 2233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.